Addition of bacterial filter alters positive airway pressure and non-invasive ventilation performances

To the Editor:

Recently, one manufacturer of home ventilators issued an alert regarding the potential risk of serious injury related to the use of some of their positive airway pressure (PAP) and non-invasive ventilation (NIV) devices [1]. The risk is caused by the polyurethane foam used in their ventilators. In some cases, the foam broke into the blower and could have been inhaled by patients. The manufacturer and some healthcare regulatory agencies advocated, as a temporary solution, to modify PAP and NIV circuits by adding an inline bacterial filter in order to reduce the risk of inhalation [2]. However, changing ventilator circuits can alter ventilator performances during PAP and NIV [3].

Auto-titrating PAP is commonly used to reduce the need for inpatient titration [4] by the use built-in algorithm to adjust the level of pressure needed to effectively treat the patient [5, 6]. However, no study has evaluated the impact of inline bacterial filter insertion on the efficacy of auto-titrating PAP. As the insertion of an inline bacterial filter has been recommended, we sought to assess the consequences of such an addition.

The aim of our study was to assess the impact of the adjunction of an inline filter in a ventilator circuit used during NIV and fixed and auto-titrating PAP.

To assess ventilator performance, we used an experimental setup made of a three-dimensional printed head mimicking human upper airways and trachea connected to an artificial lung (ASL5000, IngMar Medical, USA) as previously described [3]. We compared ventilator performances without any filter (i.e. normal use of the ventilator) and with five commercial low-resistance breathing filters: Anesth-Guard (Teleflex Medical, USA), Clear-Guard 3 (Intersurgical, UK), Clear-Guard Midi (Intersurgical, UK), Eco SlimLine (L3 Medical, France) and Flo-Guard (Intersurgical, UK).

For NIV, we used Dreamstation BiPAP AVAPS, BiPAP A40 and Trilogy 100 ventilators (Philips Respironics, USA). We used a pressure support mode; inspiratory positive airway pressure (IPAP) at 15 and 25 cmH2O; expiratory positive airway pressure (EPAP) at 5 cmH2O. We computed triggering delay (ms), inspiratory pressure-time product (PTPt) (cmH2O·s), pressure differential (cmH2O), defined as the difference between the delivered inspiratory pressure and the set pressure, and tidal volume (mL). Simulated patient–ventilator asynchrony (sPVA) events were classified according the SomnoNIV group framework [7].

For PAP, we used a DreamStation PAP device (Philips Respironics, USA). We computed regulation delay (ms), PTPt (cmH2O·s) and the maximal delivered pressure (cmH2O).

For auto-titrating PAP assessment, we simulated obstructive events by applying 10 cmH2O to a Starling resistance as previously described [8]. After 6 min without any event, 20 s length obstructive events were simulated every 60 s. A total of 24 obstructive events were simulated. We assessed the EPAP reached during the last 4 min of the simulation.

The recommendation to add a bacterial filter on home positive pressure devices has significant negative impact on their performances and precludes auto-titrating positive airway pressure to function. These data suggest not to follow such recommendation. https://bit.ly/31YrWyo

Cite this article as: Rabec C, Fresnel E, Rétery Y, et al. Addition of bacterial filter alters positive airway pressure and non-invasive ventilation performances. Eur Respir J 2022; 59: 2102636 [DOI: 10.1183/13993003.02636-2021].
Results are expressed as median and interquartile range, except for sPVA, which is expressed as mean and 95% confidence intervals. Chi-squared, Mann–Whitney, Wilcoxon and Friedman tests were used. Dunn’s correction was applied for multiple comparisons using the setup without filter as reference. All tests were two-sided. The significance level was set at 0.05. Statistical analysis was performed with Prism 9.0.0 (GraphPad Software, USA).

The addition of filter resulted in a significant impact on NIV performances with an increased triggering delay: 11 ms (9–16 ms) (p=0.010); a lower inspiratory pressure: −1.63 cmH2O (−2.10−1.1 cmH2O) (p<0.001); a lower tidal volume: −61 mL (−55−31 mL) (p=0.025); and an increase in PTPt: 1.38 cmH2O·s (0.70–1.73 cmH2O·s) (p<0.001). The addition of filters did not significantly impact the rate of sPVA: 33% (95% CI 25–41%) versus 27% (95% CI 24–31%) (p=0.261) (table 1).

Using continuous PAP (CPAP), the addition of filter resulted in an increased regulation delay: 237 ms (168–386 ms) (p<0.001); a lower inspiratory pressure: −0.81 cmH2O (−0.74–0.90 cmH2O) (p<0.001); and an increase in PTPt: 14.92 cmH2O·s (8.60–23.41 cmH2O·s) (p<0.001) (table 1).

The addition of filter resulted in a lower delivered pressure during auto-adjusting PAP: −3.18 cmH2O (−3.29–3.08 cmH2O) (p<0.001) (table 1). With auto-adjusting PAP, 93% of cycles were correctly classified as obstructive events by the device without filter. With a filter, the percentage of correctly identified events dropped down to 25% of cycles (Flo-guard) (p<0.001) (table 1).

Following recommendations suggesting the use of inline bacterial filter to reduce the risk of particle inhalation, our experimental model shows that 1) during NIV, adding a bacterial filter significantly increased the work of breathing and decreased the delivered volume; 2) during PAP, adding a bacterial filter increased the work of breathing and decreased the delivered pressure; and 3) during auto-titrating PAP, the use of bacterial filter resulted in lower pressure and inaccurate characterisation of respiratory events.

Home NIV is delivered to patients with advanced chronic respiratory failure [9] who have a poor prognosis [10]. As the addition of filters leads to an increase of work of breathing and a lower tidal volume, they may aggravate hypoventilation and thus dramatically impact on NIV efficacy and worsen prognosis. If physicians were to follow the recommendation to add an inline filter, our data suggest to closely monitor patients and to adjust NIV settings to alleviate the impact on the work of breathing and on the delivered volume.

With PAP, the delivered pressure was lower both with CPAP (−0.81 cmH2O) and auto-adjusting PAP (−3.18 cmH2O). Such a drop in the delivered pressure is likely to have clinical consequences with poorer control of upper airway.

In our study, we have demonstrated that adding an inline filter greatly altered the automated detection of obstructive events. Clinicians should therefore not base their clinical decision using the residual event data provided by a PAP device when using an inline filter.

Our results show that the addition of an inline filter could strongly impact on the effectiveness of the auto-adjusting PAP device tested. Indeed, we have shown that the addition of filters resulted in a lower delivered pressure and a higher number of residual obstructive events. We hypothesise that filters impact the efficacy of this device by interfering with the detection of obstructive respiratory events leading to an increase in the residual apnoea–hypopnoea index reported by the device. Our results show that auto-adjusting PAP should not be used with an inline filter.

In line with previous bench studies [3, 11], our results highlight that PAP and NIV devices should be used as per their user manual without any alteration on their regular setup. Indeed, any change may impair their efficacy.

There are some limitations in our study. First, we only performed a bench model study. However, a clinical trial assessing six different types of experimental condition, and three different type of lung mechanics would have not been feasible especially given the night-to-night variability [12]. Second, we identified significant differences between filters, but we did to evaluate their clinical relevance or their long-term consequences. Third, we did not assess the impact of filter insertion on the volatile organic compound. Finally, these results may not be extensible to other machines and manufacturers.
|               | No filter | Anesth-Guard filter (F1) | Clear-Guard 3 filter (F2) | Clear-Guard Midi Filter (F3) | Eco SlimLine Filter (F4) | Flo-Guard filter (F5) | p-value |
|---------------|-----------|--------------------------|---------------------------|-----------------------------|--------------------------|----------------------|---------|
| **NIV**       |           |                          |                           |                             |                          |                      |         |
| Time to trigger (ms) | 94.9 (69.2–142) | 105 (78.0–159)* | 112 (82.6–172)* | 106 (76.2–162)* | 104 (74.6–158)* | 101 (74.1–153)* | <0.001 |
| Pressure differential (cmH2O) | 0.250 (0.160–0.315) | –1.24 (–1.51–0.91)* | –1.64 (–2.15–1.22)* | –1.24 (–1.15–0.91)* | –1.44 (–1.68–1.02)* | –1.44 (–1.68–1.02)* | <0.001 |
| Tidal volume (mL) | 859 (614–946) | 815 (595–889)* | 758 (568–868)* | 793 (579–878)* | 811 (598–891)* | 829 (603–908)* | <0.001 |
| Asynchrony index (%) | 32.9 (24.6–41.2) | 25.5 (17.8–33.1) | 29.8 (22.0–37.6) | 28.4 (20.6–36.2) | 26.6 (18.8–34.4) | 25.6 (17.9–33.4) | 0.261 |
| **CPAP**      |           |                          |                           |                             |                          |                      |         |
| Regulation delay (ms) | 146 (127–206) | 374 (297–593)* | 464 (344–637)* | 412 (309–604)* | 375 (280–594)* | 331 (253–515)* | <0.001 |
| Pressure level (cmH2O) | 9.99 (9.83–10) | 9.17 (9.08–9.2)* | 8.86 (8.76–8.88)* | 9.13 (9.01–9.14)* | 9.29 (9.15–9.3)* | 9.50 (9.37–9.53) | <0.001 |
| Pressure differential (cmH2O) | 0.039 (0.033–0.040) | –0.858 (–0.863–0.852)* | –0.858 (–0.863–0.852)* | –0.858 (–0.863–0.852)* | –0.858 (–0.863–0.852)* | –0.858 (–0.863–0.852)* | <0.001 |
| PTPt insp. (cmH2O·s) | 4.47 (4.21–4.69) | 20.2 (11.9–24.8)* | 32.5 (16.8–40.3)* | 24.2 (13.2–29.7)* | 18.7 (11.6–22.8)* | 14.1 (8.91–19.1) | <0.001 |
| **Auto-adjusting PAP** |           |                          |                           |                             |                          |                      |         |
| Mask pressure (cmH2O) | 10.19 (10.16–10.22) | 6.88 (6.74–7.07)* | 7.48 (7.43–7.61)* | 7.78 (7.71–7.88)* | 6.98 (6.84–7.13)* | 7.01 (6.87–7.14)* | <0.001 |
| Apnoea–hypopnoea detected by the built-in software (n) | 14 | 24 | 24 | 24 | 24 | 24 | 0.132 |
| Central event according to built-in software | 1 (7%) | 14 (58%) | 6 (25%) | 16 (66%) | 15 (63%) | 18 (75%) | <0.001 |
| Obstructive event according to built-in software | 13 (93%) | 10 (42%) | 18 (75%) | 8 (34%) | 9 (37%) | 6 (25%) |         |
| Residual obstructive apnoeic event measured in the simulated patient¶ | 5 (21%) | 24 (100%) | 10 (42%) | 8 (33%) | 24 (100%) | 24 (100%) | <0.001 |
| Residual obstructive hypopnoeic event measured in the simulated patient¶ | 19 (79%) | 0 (0%) | 14 (58%) | 16 (77%) | 0 (0%) | 0 (0%) |         |

*: significantly different from control (no filter). ¶: residual obstructive apnoeic events were defined by a reduction of 90% of baseline flow ≥10 s measured by the artificial lung; ¶: residual obstructive hypopnoeic events were defined by a reduction between 30% and 90% of baseline flow ≥10 s measured by the artificial lung. PTPt insp.: inspiratory pressure-time product.
We have shown that the addition of inline filters has meaningful consequences for ventilator performance. The addition of these filters alters the detection of, and results in lower control of, obstructive events. Therefore, we suggest not using inline filters during auto-titrating PAP. If used during NIV and CPAP, these bacterial filters require a close monitoring and setting adjustments.

Claudio Rabec 1,2,3, Emeline Fresnel 4, Yann Rétery 5, Kaixian Zhu 5, Karima Joly 7, Adrien Kerfourn 4, Benjamin Dudoignon 6, Alexis Mendoza 3, Antoine Cuvelier 6, Jean-François Muir 2, Boris Melloni 2,8, Jean-François Chabot 2,9, Jésus Gonzalez-Bermejo 3,10,11 and Maxime Patout 3,6,11

1Pulmonary Dept and Respiratory Critical Care Unit, University Hospital Dijon, Dijon, France. 2Fédération ANTADIR, Paris, France. 3Groupe Assistance Ventilatoire et O2 (GAVO2), Société de Pneumologie de Langue Française, Paris, France. 4Kernel Biomedical, Bois-Guillaume, France. 5Centre EXPLOR, Air Liquide Healthcare, Gently, France. 6AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service des Pathologies du Sommeil (Département R3S), Paris, France. 7Normandie Univ, UNIRouen, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France. 8Pulmonary Dept, University Hospital Limoges, Limoges, France. 9Département de Pneumologie, Université de Lorraine, CHU de Nancy, Vandœuvre-lès-Nancy, France. 10AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Paris, France. 11Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.

Corresponding author: Maxime Patout (maxime.patout@aphp.fr)

Acknowledgements: Maxime Patout is the guarantor of the content of the manuscript, including the data and analysis. The authors would like to thank ANTADIR for funding the experiments and the centre EXPLOR for performing the experiments with auto-titrating PAP; and ASV santé, Jean-Christian Borel and M. Philippe Roussel from AGIRADOM (Grenoble).

Author contributions: C. Rabec, E. Fresnel, K. Zhu, Y. Rétery, K. Joly, J. Gonzalez-Bermejo and M. Patout: conception, acquisition, analysis, interpretation, drafting the work, revising critically; A. Mendoza, A. Cuvelier, B. Dudoignon, B. Melloni, A. Kerfourn, J-F. Muir and J-F. Chabot: conception, interpretation and revising critically.

Conflict of interest: In the last 2 years, C. Rabec received fees from Philips, Resmed, Lowenstein and Fischer & Paykel for expertise, outside the submitted work. M. Patout reports personal fees from Resmed, Philips Respironics, grants and non-financial support from Fisher & Paykel, nonfinancial support and personal fees from Asten and ANTADIR, research grants from B&D Electromedical and Fisher & Paykel, shares in Kernel Biomedical, personal fees and non-financial support from Chiesi, outside the submitted work. In the last 2 years, J. Gonzalez-Bermejo received fees from Philips, Resmed, Breas, Lowenstein and Air Liquide for expertise, and a grant from BREAS for a trial, outside the submitted work. E. Fresnel, Y. Rétery, K. Zhu, K. Joly, A. Kerfourn, B. Dudoignon, A. Mendoza, A. Cuvelier, J-F. Muir, B. Melloni and J-F. Chabot report no competing interests.

Support statement: This work was supported by Antadir. Funding information for this article has been deposited with the Crossref Funder Registry.

References
1 Philips Respironics. Medical Device Recall. 2021. www.philips.com/c-dam/b2bhc/master/landing-pages/src/update/documents/philips-recall-letter-2021-05-a-2021-06-a.pdf
2 American Academy of Sleep Medicine. AASM Guidance in Response to Philips Recall of PAP Devices. 2021. https://aasm.org/clinical-resources/guidance-philips-recall-pap-devices/ Date last updated: 16 November 2021.
3 Patout M, Fresnel E, Lujan M, et al. Recommended approaches to minimize aerosol dispersion of SARS-CoV-2 during noninvasive ventilatory support can cause ventilator performance deterioration: a benchmark comparative study. Chest 2021; 160: 175–186.
4 Bloch KE, Huber F, Furian M, et al. Autoadjusted versus fixed CPAP for obstructive sleep apnoea: a multicentre, randomised equivalence trial. Thorax 2018; 73: 174–184.
5 Scharf MB, Brannen DE, McDannold MD, et al. Computerized adjustable versus fixed NCPAP treatment of obstructive sleep apnea. Sleep 1996; 19: 491–496.
6 Rigau J, Montserrat JM, Wohrle H, et al. Bench model to simulate upper airway obstruction for analyzing automatic continuous positive airway pressure devices. Chest 2006; 130: 350–361.
7 Gonzalez-Bermejo J, Janssens JP, Rabec C, et al. Framework for patient-ventilator asynchrony during long-term non-invasive ventilation. Thorax 2019; 74: 715–717.
8 Zhu K, Rabec C, Gonzalez-Bermejo J, et al. Combined effects of leaks, respiratory system properties and upper airway patency on the performance of home ventilators: a bench study. BMC Pulm Med 2017; 17: 145.
9 Cantero C, Adler D, Pasquina P, et al. Long-term noninvasive ventilation in the Geneva Lake area: indications, prevalence, and modalities. Chest 2020; 158: 279–291.
10 Patout M, Lhuillier E, Kaltsakas G, et al. Long-term survival following initiation of home non-invasive ventilation: a European study. Thorax 2020; 75: 965–973.
11 Delorme M, Leroux K, Boussaid G, et al. Protective recommendations for non-invasive ventilation during COVID-19 pandemic: a bench evaluation of the effects of instrumental dead space on alveolar ventilation. Arch Bronconeumol 2021; 57: 28–33.
12 Roeder M, Sievi NA, Bradicich M, et al. The accuracy of repeated sleep studies in OSA: a longitudinal observational study with 14 nights of oxygen saturation monitoring. Chest 2021; 159: 1222–1231.